Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Capsules × Plasma cell × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Genitourinary 1

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Dexamethasone 321 Lenalidomide 170 Bortezomib 170 Cyclophosphamide 154 Melphalan 117 Calcium Dobesilate 102 daratumumab 92 carfilzomib 62 pomalidomide 61 fludarabine phosphate 55 Peripheral Blood Stem Cell Transplantation 55 Thalidomide 48 Filgrastim 47 Mycophenolic Acid 45 Busulfan 44 ixazomib 41 fludarabine 39 Whole-Body Irradiation 37 Granulocyte Colony-Stimulating Factor 37 Tacrolimus 36 dexamethasone acetate 32 Etoposide 29 isatuximab 28 Cyclosporine 28 Antilymphocyte Serum 28 dexamethasone 21-phosphate 26 auricularum 24 elotuzumab 23 plerixafor 22 Radiotherapy 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02756663 2016-11-08

PANORAMA-5

Novartis

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡